CT-868
A Study of CT-868 in Type 1 Diabetes Mellitus
Carmot Therapeutics, Inc · Phase 2 · Completed · Enrollment 111
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| CT-868 Low Dose | Obesity + T2D | n/r | 16 | n/r | n/r |
| CT-868 Medium Dose | Obesity + T2D | n/r | 16 | n/r | n/r |
| CT-868 High Dose | Obesity + T2D | n/r | 16 | n/r | n/r |
| CT-868 Placebo | Obesity + T2D | n/r | 16 | n/r | n/r |
| Arm 2: CT-868 Titrated to 1.8 mg | Obesity + T2D | 1.8 mg | 16 | n/r | n/r |
| Arm 3: CT-868 Titrated to 4.1 mg | Obesity + T2D | 4.1 mg | 16 | n/r | n/r |
| Arm 4: CT-868 Titrated to 6.6 mg | Obesity + T2D | 6.6 mg | 16 | n/r | n/r |